With 90% of assets entering clinical trials failing to reach the market and R&D costs continuing to rise, it is more important than ever for pharmaceutical companies to understand the value of their portfolios.
Are you failling fast enough to minimize investment in those failing programs? While the industry has relied on benchmarks to forecast timelines and probabilities of success, we now have technology available to predict failures faster and more accurately.
Read our white paper to learn more about how we are using advanced statistical modeling with machine learning to bring you pipeline forecasting that is data-backed, dynamic, and constantly improving.